Dabigatran Plasma Measurement to Guide the Management of Acute Bleeding and Thrombotic Complications

Authors

• Maurizio Tala Haemostasis and Thrombosis Center, ASST Cremona, Cremona, Italy
• Oriana Paoletti Haemostasis and Thrombosis Center, ASST Cremona, Cremona, Italy
• Claudia Dellanoce Haemostasis and Thrombosis Center, ASST Cremona, Cremona, Italy
• Rossella Morandini Haemostasis and Thrombosis Center, ASST Cremona, Cremona, Italy
• Carlo Valtulina Division of Neurosurgery, ASST Cremona, Cremona, Italy
• Maria Sessa Division of Neurology, ASST Cremona, Cremona, Italy
• Sophie Testa Haemostasis and Thrombosis Center, ASST Cremona, Cremona, Italy

s.testa@asst-cremona.it

Keywords

Abstract

Oral anticoagulant therapy is recommended for the prevention and treatment of venous thromboembolism and to prevent stroke in non-valvular atrial fibrillation. Until a few years ago, vitamin K antagonists were the only drugs available, but direct oral anticoagulants have recently been introduced into clinical practice for the same clinical indications. Unlike the situation with VKAs, fixed-dose administration was proposed for DOACs, without the necessity for routine laboratory monitoring. However, in clinical practice a high inter-variability in DOAC plasma levels, independently of the type of drug and patient characteristics, was observed and the importance of measuring DOAC anticoagulant activity to support treatment decisions has therefore been recognized. We describe two clinical cases in order to highlight the role and importance of dabigatran-specific measurements to guide patient management in case of major complications.